Q-omics provides the consensus-scored PRSS41 profile across patient tissues and cancer cell-line models. PRSS41 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PRSS41 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, PRSS41 RNA expression shows 9,076 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where PRSS41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS41 survival associations across molecular data types. PRSS41 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS41 RNA expression–survival associations across cancer types. High PRSS41 expression shows unfavorable associations in THCA, KIRC and BRCA, but favorable associations in HNSC, PAAD and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for PRSS41 RNA expression.
This table summarizes PRSS41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRSS41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS41 shows lower tumor expression in LUAD and higher tumor expression in COAD, READ and BRCA. The COAD box plot shows higher PRSS41 RNA expression in tumor versus normal tissue (log2 FC = +0.977, t-test p < 0.001).
This table shows molecular features associated with PRSS41 in patient tissues and cancer cell lines. In patient samples, PRSS41 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
